Manufacturers Life Insurance Company, The Mei Pharma, Inc. Transaction History

Manufacturers Life Insurance Company, The

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $23,123 - $35,785	-55,055 Closed	0 $0
Q1 2022 Aug 11, 2023	BUY	$0.54 - $2.74 $29,729 - $150,850	55,055 New	55,055 $33,000
Q1 2022 May 20, 2022	SELL	$0.54 - $2.74 $5,712 - $28,983	-10,578 Reduced 16.12%	55,055 $33,000
Q4 2021 Feb 16, 2022	SELL	$2.33 - $3.37 $3,972 - $5,745	-1,705 Reduced 2.53%	65,633 $175,000
Q3 2021 Nov 12, 2021	SELL	$2.52 - $2.99 $4,541 - $5,387	-1,802 Reduced 2.61%	67,338 $186,000
Q2 2021 Aug 12, 2021	BUY	$2.6 - $3.65 $2,951 - $4,142	1,135 Added 1.67%	69,140 $197,000
Q1 2021 May 03, 2021	SELL	$2.73 - $4.5 $13,098 - $21,591	-4,798 Reduced 6.59%	68,005 $233,000
Q4 2020 Feb 12, 2021	BUY	$2.6 - $3.32 $23,940 - $30,570	9,208 Added 14.48%	72,803 $192,000
Q2 2020 Aug 10, 2020	BUY	$1.45 - $4.3 $4,247 - $12,594	2,929 Added 4.83%	63,595 $262,000
Q1 2020 May 15, 2020	BUY	$0.75 - $2.55 $10,188 - $34,639	13,584 Added 28.85%	60,666 $98,000
Q4 2019 Feb 14, 2020	SELL	$1.65 - $2.48 $8,492 - $12,764	-5,147 Reduced 9.85%	47,082 $117,000
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $127,961 - $173,400	52,229 New	52,229 $131,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.